These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 1014494

  • 1. [Use of lophenal in patients with malignant ovarian tumors].
    Kotova DG, Razgovorova ZK.
    Vopr Onkol; 1976; 22(10):51-7. PubMed ID: 1014494
    [Abstract] [Full Text] [Related]

  • 2. [Antitumor activity of nitrocaphane (AT-1258)].
    Zhonghua Yi Xue Za Zhi; 1974; (11):693-6, 193. PubMed ID: 4215631
    [No Abstract] [Full Text] [Related]

  • 3. [1st experiences in the treatment of ovarian tumors with Peptichemio].
    Natale N, Mangioni C, Remotti G.
    Minerva Med; 1974 May 02; 65(33):1805-10. PubMed ID: 4367233
    [No Abstract] [Full Text] [Related]

  • 4. Drugs that make cancer retreat.
    Blokhin NN.
    Indian J Cancer; 1976 Sep 02; 13(3):296-8. PubMed ID: 795765
    [No Abstract] [Full Text] [Related]

  • 5. Ploidy studies in ovarian cancer during cytostatic treatment.
    Siracký J.
    Neoplasma; 1969 Sep 02; 16(4):427-33. PubMed ID: 5344228
    [No Abstract] [Full Text] [Related]

  • 6. [Comparison of the effects of Cyclophosphamide, Cytembena and Ypenyl in the treatment of inoperable ovarian neoplasms].
    Skoda V, Elis J, Jandová A, Laurová L, Novotná J, Perlík J.
    Cesk Gynekol; 1971 Sep 02; 36(7):431-3. PubMed ID: 5110665
    [No Abstract] [Full Text] [Related]

  • 7. [Experiences on in vitro testing of cytostatic sensitivity (oncobiogram) in gynecological tumors].
    Krafft W, Preibsche W, Marzotko F.
    Arch Geschwulstforsch; 1973 Sep 02; 41(3):241-7. PubMed ID: 4732846
    [No Abstract] [Full Text] [Related]

  • 8. Chemotherapy of ovarian cancer.
    Hreshchyshyn MM, Graham JB.
    Int Surg; 1967 Apr 02; 47(4):398-401. PubMed ID: 4962186
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of effects of cyclophosphamide, Cytembena, and Ypenyl in the treatment of inoperable ovarian carcinoma.
    Skoda V, Elis J, Jandová A, Laurová L, Novotná J, Perlík F.
    Neoplasma; 1971 Apr 02; 18(5):471-2. PubMed ID: 5165867
    [No Abstract] [Full Text] [Related]

  • 10. [Effect of a new cytostatic agent (peptichemio) on malignant neoplasms].
    Pittermann E, Stacher A, Griendl W.
    Wien Med Wochenschr; 1974 Apr 06; 124(14):216. PubMed ID: 4522966
    [No Abstract] [Full Text] [Related]

  • 11. [Antitumor polychemotherapy].
    Alberto P.
    Poumon Coeur; 1968 Apr 06; 24(1):21-6. PubMed ID: 5652203
    [No Abstract] [Full Text] [Related]

  • 12. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
    Giavazzi R, Garofalo A, Ferri C, Lucchini V, Bone EA, Chiari S, Brown PD, Nicoletti MI, Taraboletti G.
    Clin Cancer Res; 1998 Apr 06; 4(4):985-92. PubMed ID: 9563894
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of malignant lymphoma with Peptichemio. Preliminary communication].
    Uszyński L, Maj S, Pawelski S.
    Acta Haematol Pol; 1974 Apr 06; 5(2):153-7. PubMed ID: 4599294
    [No Abstract] [Full Text] [Related]

  • 14. [Polychemotherapy in patients with ovarian cancer].
    Kotova DG, Nechaeva ID, Vinokurov VL, Zel'dovich DR, Khasanova DT.
    Vopr Onkol; 1980 Apr 06; 26(6):7-11. PubMed ID: 7385734
    [Abstract] [Full Text] [Related]

  • 15. Soviet antitumor preparations.
    Borisov VI.
    Natl Cancer Inst Monogr; 1977 Mar 06; (45):235-44. PubMed ID: 73136
    [No Abstract] [Full Text] [Related]

  • 16. [Changes in erythropoiesis in patients with malignant tumors of the ovaries during chemotherapy].
    Bruk AA, Loskutova GP, Turbina IL.
    Vopr Onkol; 1967 Mar 06; 13(12):21-3. PubMed ID: 4970401
    [No Abstract] [Full Text] [Related]

  • 17. [The efficacy of intralymphatic use of antiblastic drugs].
    Stengrevits AA.
    Vopr Onkol; 1969 Mar 06; 15(3):3-8. PubMed ID: 5002346
    [No Abstract] [Full Text] [Related]

  • 18. [Combination chemotherapy in the treatment of cancer].
    Goldenson Y, Lev L, Robinson E.
    Harefuah; 1972 Aug 15; 83(4):157-60. PubMed ID: 4628451
    [No Abstract] [Full Text] [Related]

  • 19. Bendamustine: a new therapeutic option for hematologic malignancies.
    Cheson BD.
    Clin Adv Hematol Oncol; 2008 Sep 15; 6(9):631-3. PubMed ID: 18827785
    [No Abstract] [Full Text] [Related]

  • 20. Phase II study of spirogermanium in advanced ovarian malignancy.
    Tropé C, Mattsson W, Gynning I, Johnsson JE, Sigurdsson K, Orbert B.
    Cancer Treat Rep; 1981 Sep 15; 65(1-2):119-20. PubMed ID: 6261944
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.